The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human.

The present invention provides methods of preventing and/or reducing risk of neurodegeneration of association cortex, and/or inhibiting or reversing formation of phosphorylated tau or COXIV in the prefrontal cortex of a mammal in need thereof. In certain embodiments, the method comprises administering to the mammal a therapeutically effective amount of an α.sub.2A-adrenergic receptor agonist.

The present invention provides methods of preventing and/or reducing risk of neurodegeneration of association cortex, and/or inhibiting or reversing formation of phosphorylated tau or COXIV in the prefrontal cortex of a mammal in need thereof. In certain embodiments, the method comprises administering to the mammal a therapeutically effective amount of an α.sub.2A-adrenergic receptor agonist.

The present disclosure describes single agent and combination therapies and uses for the treatment of cancer and/or cancer-associated diseases. The single agent and combinations therapies include a BCMA antibody.

The present disclosure describes single agent and combination therapies and uses for the treatment of cancer and/or cancer-associated diseases. The single agent and combinations therapies include a BCMA antibody.

The present invention relates to compositions for facilitating absorption and distribution of α.sub.2-adrenergic agonists, where said composition comprises a substituted benzofuroquinolizine and a α.sub.2-adrenoceptor agonist selected from substituted imidazoles and substituted thiazines and the composition is administered using parenteral extravascular administration to a subject in need of sedation.

The present invention relates to compositions for facilitating absorption and distribution of α.sub.2-adrenergic agonists, where said composition comprises a substituted benzofuroquinolizine and a α.sub.2-adrenoceptor agonist selected from substituted imidazoles and substituted thiazines and the composition is administered using parenteral extravascular administration to a subject in need of sedation.

The present invention relates to compositions for facilitating absorption and distribution of α.sub.2-adrenergic agonists, where said composition comprises a substituted benzofuroquinolizine and a α.sub.2-adrenoceptor agonist selected from substituted imidazoles and substituted thiazines and the composition is administered using parenteral extravascular administration to a subject in need of sedation.

Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.